Screener
Avalo Therapeutics AVTX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's restricted cash?
- Avalo Therapeutics (AVTX) reported restricted cash of $49K in Q2 2026.
- How has Avalo Therapeutics's restricted cash changed year-over-year?
- Avalo Therapeutics's restricted cash increased by 145.0% year-over-year, from $20K to $49K.
- What is the long-term trend for Avalo Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), Avalo Therapeutics's restricted cash has grown at a -0.5% compound annual growth rate (CAGR), from $38K to $37K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Avalo Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude